[68Ga]Ga-RM26 PET/CT对[68Ga]Ga-PSMA-617 PET/CT检测前列腺癌盆腔淋巴结转移的附加价值:一项前瞻性、单中心、II期研究
这项前瞻性单中心II期研究纳入68例初诊未治疗前列腺癌患者,均行[68Ga]Ga-RM26 PET/CT与[68Ga]Ga-PSMA-617 PET/CT,随后行根治性前列腺切除及扩大盆腔淋巴结清扫。病理盆腔淋巴结转移率为30.9%(21/68)。[68Ga]Ga-RM26 PET/CT可检出[68Ga]Ga-PSMA-617 PET/CT遗漏的盆腔淋巴结转移,两者联合诊断灵敏度提高而特异性轻微下降。
要点
- 患者分析中,[68Ga]Ga-RM26 PET/CT检出50%(5/10)被[68Ga]Ga-PSMA-617 PET/CT遗漏的盆腔淋巴结转移患者。
- 病灶分析中,[68Ga]Ga-RM26 PET/CT识别41.4%(12/29)被[68Ga]Ga-PSMA-617 PET/CT遗漏的病理阳性淋巴结。
- 两者联合患者分析灵敏度0.76、特异性0.85;病灶分析灵敏度0.71、特异性0.99。
核心结论
- 在双靶点显像中,[68Ga]Ga-RM26 PET/CT可识别额外的盆腔淋巴结转移。
- [68Ga]Ga-RM26 PET/CT与[68Ga]Ga-PSMA-617 PET/CT联合获得更高的诊断灵敏度,特异性损失极小。
研究设计与样本
- 前瞻性、单中心、II期研究,纳入初诊未治疗前列腺癌患者,均行[68Ga]Ga-RM26 PET/CT与[68Ga]Ga-PSMA-617 PET/CT,随后行根治性前列腺切除及扩大盆腔淋巴结清扫。
- 共纳入68例患者,病理盆腔淋巴结转移率为30.9%(21/68)。
- 共清扫1,049枚淋巴结,其中正常991枚、阳性58枚。
主要发现
- 患者分析中,[68Ga]Ga-RM26 PET/CT灵敏度0.43、特异性0.94;[68Ga]Ga-PSMA-617 PET/CT灵敏度0.52、特异性0.89。
- 患者分析中,[68Ga]Ga-RM26 PET/CT在50%(5/10)被[68Ga]Ga-PSMA-617 PET/CT遗漏的患者中检出额外盆腔淋巴结转移。
- 患者分析中,两者联合灵敏度0.76、特异性0.85。
- 病灶分析中,[68Ga]Ga-RM26 PET/CT灵敏度0.38、特异性0.99;[68Ga]Ga-PSMA-617 PET/CT灵敏度0.5、特异性0.99。
- 病灶分析中,[68Ga]Ga-RM26 PET/CT识别41.4%(12/29)被[68Ga]Ga-PSMA-617 PET/CT遗漏的病理阳性淋巴结;两者联合灵敏度0.71、特异性0.99。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lymph node staging in prostate cancer is crucial for treatment and prognosis, yet [68Ga]Ga-PSMA-617 PET/CT has limited sensitivity in detecting pelvic lymph node metastasis (PLNM). [68Ga]Ga-RM26 PET/CT, targeting the gastrin-releasing peptide receptor, complements [68Ga]Ga-PSMA-617 PET/CT in assessing primary tumor extension and aggressiveness. However, its role in detecting PLNM and complementing [68Ga]Ga-PSMA-617 PET/CT remains underexplored. Methods: This prospective study enrolled newly diagnosed yet untreated prostate cancer patients who underwent [68Ga]Ga-RM26 PET/CT and [68Ga]Ga-PSMA-617 PET/CT, followed by radical prostatectomy and extended pelvic lymph node dissection. The primary objective was to evaluate the diagnostic performance of both PET/CT modalities in detecting PLNM. Results: In total, 68 patients were enrolled, with a 30.9% (21/68) pathologic PLNM rate. In patient-based analysis, [68Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.43 and 0.94, respectively, compared with 0.52 and 0.89 for [68Ga]Ga-PSMA-617 PET/CT. [68Ga]Ga-RM26 PET/CT detected additional PLNMs in 50% (5/10) of patients that were missed by [68Ga]Ga-PSMA-617 PET/CT. The combined use of [68Ga]Ga-RM26 PET/CT and [68Ga]Ga-PSMA-617 PET/CT resulted in sensitivity of 0.76 and specificity of 0.85. In total, 1,049 lymph nodes were dissected, including 991 normal and 58 positive nodes. In lesion-based analysis, [68Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.38 and 0.99, respectively, compared with 0.5 and 0.99 for [68Ga]Ga-PSMA-617 PET/CT. [68Ga]Ga-RM26 PET/CT identified 41.4% (12/29) of pathologic positive nodes missed by [68Ga]Ga-PSMA-617 PET/CT. The combined [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT demonstrated sensitivity of 0.71 and specificity of 0.99. Conclusion: In dual-target imaging, [68Ga]Ga-RM26 PET/CT identified additional PLNMs. The combination of [68Ga]Ga-RM26 PET/CT and [68Ga]Ga-PSMA-617 PET/CT achieved higher diagnostic sensitivity with minimal loss of specificity.
引用
- Tang W, Qi L, Chen M, et al. Additive Value of [68Ga]Ga-RM26 PET/CT to [68Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study. J Nucl Med. 2025. PMID: 40113221. doi:10.2967/jnumed.124.269189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。